Effect of rosuvastatin with dose 40 mg compared to placebo on nerve conduction velocity in64 patients with carpal tunnel syndrome

Phase 3

Recruiting

Conditions: Carpal tunnel syndrome.
Carpal tunnel syndrome, unspecified upper limb
G56.00

Registration Number: IRCT20231020059773N1

Lead Sponsor: Qazvin University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 64

Inclusion Criteria

People who, in terms of clinical symptoms, have suspicious symptoms related to carpal tunnel syndrome (including pain, paresthesia, and numbness in the area of ??the median nerve)
People whose CTS is confirmed by electrodiagnostic tests.

Exclusion Criteria

- Subjects should not be treated with any drug from the statin group.
??people with hypothyroidism
people with connective tissue diseases
people with rheumatoid arthritis
people with malignancy including Lipoma/ hemangioma
/ people with infectious and inflammatory diseases including sarcoidosis/ septic arthritis
any trauma and local bleeding
hemodialysis/ pregnancy/ any conditions that cause edema and increase in total body fluid
people with cts with grade severe refers to this group in terms of clinical symptoms of people who have hypotrophy and atrophy of the thenar muscle or people who were classified as grade/severe based on electrodiagnostic tests

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity of carpal tunnel disease. Timepoint: Start of the study/three months after the start of the study. Method of measurement: Electrodiagnostic tests/questionnaire.;AMPLITUDE of Median nerve. Timepoint: Start of the study/three months after the start of the study. Method of measurement: Electrodiagnostic tests/questionnaire.;LATENCY of Median nerve. Timepoint: Start of the study/three months after the start of the study. Method of measurement: Electrodiagnostic tests/questionnaire.;BMI. Timepoint: Start of the study. Method of measurement: questionnaire.

Secondary Outcome Measures

Name	Time	Method
Reduction of clinical symptoms of patients including paresthesia and pain and. Timepoint: Beginning of the study/ three months after the beginning of the study. Method of measurement: questionnaire.